Skip to main content
Evidence Snapshot

Prostaglandin F2-alpha receptor

CHEMBL1987 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:37Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1987
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Prostaglandin F2-alpha receptor as ChEMBL target CHEMBL1987, mapped to UniProt P43088. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Prostaglandin F2-alpha receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1987
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P43088
Prostaglandin F2-alpha receptor
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Prostaglandin F2-alpha receptor matters

As of 2026-09-14

Prostaglandin F2-alpha receptor is reviewed as Prostaglandin F2-alpha receptor (UniProt P43088); Prostaglandin F2-alpha receptor shows approved-linked disease relevance led by glaucoma. 5 more disease programs remain visible in the same review block.; 5 linked drugs keep this evidence frame grounded.; the current evidence base includes 5 approved drugs, 855 compounds, and 104 assays, with lead potency reaching pChEMBL 9.3.

Disease context
glaucoma

Prostaglandin F2-alpha receptor shows approved-linked disease relevance led by glaucoma. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include BIMATOPROST, LATANOPROST, LATANOPROSTENE BUNOD.

Start review with glaucoma because it currently carries approved-linked support. Linked drugs include BIMATOPROST, LATANOPROST, LATANOPROSTENE BUNOD, TAFLUPROST. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 5 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 5 approved drugs, 855 compounds, and 104 assays for this target. The dominant activity type is IC50. CHEMBL4752237 is the current potency anchor at pChEMBL 9.3.

Use CHEMBL4752237 as the tractability anchor when discussing potency (pChEMBL 9.3).

Activity source · ChEMBL 36 via Core Engine
5 approved pChEMBL 9.3
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Prostaglandin F2-alpha receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P43088, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why glaucoma is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

855
Total Compounds
104
Total Assays
5
Approved Drugs
IC50: 556.0, KI: 126.0, EC50: 165.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4752237
 9.3 IC50 —
No preferred name
CHEMBL4749822
 9.1 IC50 —
No preferred name
CHEMBL6015710
 9.0 IC50 —
No preferred name
CHEMBL2220404
 9.0 IC50 Clinical
No preferred name
CHEMBL36041
 9.0 IC50 —

Approved Drugs

Structure Compound First Approval
DINOPROST
CHEMBL815
 1982
DINOPROSTONE
CHEMBL548
 1977
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:37Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1987